NOVONIX CEO reports 5.86M performance rights

NOVONIX Ltd director and Chief Executive Officer Michael O'Kronley reported his existing derivative holdings in the form of performance rights.

Accepted by SEC EDGAR 05/05/2026 - 07:50 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

NOVONIX Ltd director and Chief Executive Officer Michael O'Kronley reported his existing derivative holdings in the form of performance rights. These rights relate to 5,862,567 underlying ordinary shares, have an exercise price of $0.0000, become exercisable on December 31, 2028, and expire on December 31, 2029. The entry is recorded as a holding, with no buy or sell transaction reported.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider O'Kronley Michael

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Holding	Performance rights	--	--	--

Holdings: Performance rights — 5,862,567 contracts (Direct)

Key Figures

Underlying shares: 5,862,567 shares Exercise price: $0.0000 per share Exercise start date: December 31, 2028 +1 more

4 metrics

Underlying shares 5,862,567 shares Underlying ordinary shares linked to performance rights

Exercise price $0.0000 per share Exercise price for performance rights

Exercise start date December 31, 2028 Date performance rights become exercisable

Expiration date December 31, 2029 Expiration of performance rights

Key Terms

Performance rights, Ordinary shares, Derivative securities

3 terms

Performance rights financial

"security_title: "Performance rights""

Performance rights are conditional awards that give employees or executives the promise of receiving company shares or cash only if the business meets specific targets or survives for a set period. They work like a bonus you only get when certain goals are hit, so they matter to investors because they can increase the number of shares outstanding (dilution), signal management’s incentives and confidence in future results, and affect per-share earnings and valuation.

Ordinary shares financial

"underlying_security_title: "Ordinary shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Derivative securities financial

"derivativeSummary lists performance rights as derivative holdings"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NOVONIX (NVX) CEO Michael O'Kronley report in this Form 4?

Michael O'Kronley reported his existing holding of performance rights linked to 5,862,567 NOVONIX ordinary shares. The filing shows a derivative position, not a new purchase or sale, and reflects his post-reporting holdings in these rights.

How many NOVONIX shares are tied to the CEO’s performance rights?

The performance rights reported by NOVONIX CEO Michael O'Kronley are linked to 5,862,567 underlying ordinary shares. These represent potential future shares, subject to the rights’ terms, rather than shares currently acquired through a market transaction.

When can the NOVONIX CEO’s performance rights be exercised?

Michael O'Kronley’s performance rights become exercisable on December 31, 2028. After that date, they can be converted into NOVONIX ordinary shares according to their terms, up until their stated expiration date in late 2029.

What is the exercise price of the NOVONIX CEO’s performance rights?

The exercise price for Michael O'Kronley’s performance rights is $0.0000 per underlying ordinary share. This means there is no cash exercise cost specified for converting the rights into shares during the exercise period.

Do the NOVONIX Form 4 details show any insider buying or selling?

This Form 4 does not show insider buying or selling of NOVONIX shares. It records a holding of derivative securities—performance rights—rather than an open-market purchase, sale, gift, or other transfer of ordinary shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Kronley Michael

(Last) (First) (Middle)

1029 WEST 19TH STREET

(Street)

CHATTANOOGA TENNESSEE 37408

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NOVONIX Ltd [ NVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance rights	$0							12/31/2028	12/31/2029	Ordinary shares	5,862,567		9,586,538	D

Explanation of Responses:

Remarks:

Issue of performance rights to Michael O'Kronley following shareholder approval at the AGM on April 15, 2026.

	Suzanne Yeates	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)